IRVINE, Calif., June 17, 2011 /PRNewswire/ -- ResearchDx, LLC of Irvine, California today announced a strategic partnership with CompanDX of Nottingham UK. ResearchDx and CompanDX have forged a unique partnership to offer a full capability to discover and deliver novel molecular diagnostic tests for clients in the healthcare setting. CompanDX uses its unique “Distiller” platform to deliver small composite biomarker signatures from complex data of high dimensionality, which are commonplace in clinical development of therapeutics. ResearchDx draws on its broad capability to design, produce and validate tests ready for the market and represents a new breed of service provider, the first CDO to offer turnkey solutions for companion diagnostic delivery.
“Our partnership with CompanDX completes our service offerings,” said Founders of ResearchDx, Dr. Philip Cotter and Dr Mathew Moore. “CompanDX’s unique capabilities allow us to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process. Our customers can trust ResearchDx to meet scientific challenges with a focus on their business priorities.”
The new partnership will allow clients to initiate the parallel development of companion diagnostic tests from the very earliest stages of drug development. CompanDX has developed a set of industry-leading tools to deliver definitive understanding of mechanism of action and biomarkers that describe patient response. Andy Sutton, CEO of CompanDX commented, “ResearchDx occupies a space in the development of companion diagnostics that is highly complementary with our discovery platform. Both companies strive to provide innovative solutions, cutting-edge capabilities, and outcome focused delivery. We are thrilled to dovetail into ResearchDx’s downstream delivery by providing the biomarkers tailored to client’s drug candidates that will form the basis of validated tests for use in the clinic.”
ResearchDx is a Contract Diagnostics Organization (CDO) for the biopharmaceutical and diagnostic industries. The company provides comprehensive, integrated, flexible services for the in vitro diagnostic development process. From initial assay conceptualization, discovery, optimization and validation in a CAP/CLIA laboratory environment, through a complete set of clinical research services and on to regulatory approval, ResearchDx offers the services and solutions to meet complex diagnostics development needs. ResearchDx’s primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting. Additional information is available at www.researchdx.com. ResearchDx will be exhibiting at DIA 2011 in Chicago, IL, June 19 22, booth #1238 and Chairing the session “Pharma-Diagnostics Relationship” at the Next Generation DX Summit in Washington D.C., August 23 25, 2011.
CompanDX is a molecular diagnostics company focused on biomarker discovery that uses its unique “Distiller” platform to derive small composite biomarker panels defining patient populations of significant unmet need. Working with Pharma and biotech companies CompanDX offers the opportunity to deliver stratified clinical trials utilizing companion diagnostic tests based on biomarkers derived from the “Distiller” bioinformatics platform. Privately-held, CompanDX is based in Nottingham, UK. Investors in the company include Lachesis and Mobius Funds. Additional information is available at www.compandx.com
Media Contact:
Philip D. Cotter, PhD, FACMG, FFSc (RCPA)
ResearchDx
Suite 147, 13766 Alton Parkway
Irvine, CA 92618
info@researchdx.com
866-225-9195 / 510-332-0477
SOURCE ResearchDx
